Highest-materiality recent filing
12 patients treated; 7 lived beyond expected median survival of 3-4 months; one survived 28 months.
Vaccine met all primary endpoints; 74% of participants showed protocol-defined aLA-specific T cell responses.
Phase 1 trial of alpha-lactalbumin vaccine updated at SITC; data continue positive trend across 3 cohorts.
Anixa expands Cleveland Clinic joint development to develop additional cancer vaccines
Anixa and Cleveland Clinic entered Joint Development and Option Agreement to develop vaccines for multiple cancers.
Anixa reports positive Phase 1 breast cancer vaccine data; T-cell responses in 75% of patients
16 TNBC patients treated; 12/16 (75%) developed antigen-specific T-cell responses at all dose levels.
Anixa Biosciences and Cleveland Clinic report positive Phase 1 data for breast cancer vaccine
Phase 1 trial of triple-negative breast cancer vaccine showed antigen-specific T cell responses at all dose levels.
Anixa Biosciences reaches maximum tolerated dose in Phase 1a trial of breast cancer vaccine
Maximum tolerated dose achieved in Phase 1a trial of preventative breast cancer vaccine.
Anixa Biosciences doses first patient in Phase 1 CAR-T trial for ovarian cancer
First patient dosed in Phase 1 trial of novel CER-T therapy for ovarian cancer at Moffitt Cancer Center.
On April 14, 2022, the Board of Directors of Anixa Biosciences, Inc. (“we,” “us,” “our,” or the “Company”) promoted Michael Catelani, the current Chief Operating Officer and Chief Financial Officer of the Company, to President of the Company effective immediately.
Mr. Catelani is replacing Dr. Amit Kumar, the prior President and current Chairman and Chief Executive Officer of the Company.
Max materiality 0.80 · Median 0.53 · Most common event other_material